Feedback / Questions
VENT-04 - Ventus Therap
https://www.businesswire.com/news/home/20260106803008/en/Ventus-Therapeutics-Announces-Nomination-of-VENT-04-a-First-in-Class-Oral-Small-Molecule-Caspase-45-Inhibitor-as-a-Development-Candidate
Jan 7, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next